| |
Centre for Policy on Ageing | |
 | |
|
| A randomized trial evaluating the efficacy and safety of ENA (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease | | Author(s) | J Corey-Bloom, R Anand, J Veach |
| Journal title | International Journal of Geriatric Psychopharmacology, vol 1, 1998 |
| Pages | pp 55-65 |
| Keywords | Dementia ; Drugs ; Evaluation ; United States of America. |
| Annotation | The results of this large, controlled multicentre US study provide strong evidence of the efficacy of ENA 713 (rivastigmine tartrate) in treating key cognitive, behavioural, and functional symptoms of mild to moderate Alzheimer's disease (AD). Unlike patients receiving placebo, who steadily deteriorated, those treated with high-dose ENA 713 were able to maintain their baseline level of performance on the AD Assessment Scale - Cognitive subscale (ADAS-Cog) throughout the 26 week treatment trial; they also showed less deterioration on the CIBC-Plus (Clinician's Interview Based Impression of Change-Plus) ratings. On the Progressive Deterioration Scale (PDS), the high dose vs placebo difference was significant. No differences were noted between groups regarding electrocardiograms, laboratory evaluations, or vital signs. A higher incidence of gastro-intestinal adverse events, which were self-limited and of mild to moderate intensity, were noted with ENA 713. The trial concludes that ENA 713 is safe and effective with regard to cognition, global functioning and activities of daily living in patients with mild to moderately severe AD. (RH). |
| Accession Number | CPA-980828206 A |
| Classmark | EA: LLD: 4C: 7T * |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|